Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | POLQ | O75417 | 9/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3312802 | 0.84 | POLQ (0.39) | ALDH1A1POLQNR1H3KMT2AKDM4E | |
| SCHEMBL2913174 | 0.71 | RIPK1 (0.44) | ALDH1A1POLQNR1H3MEN1KMT2A | |
| SCHEMBL13830993 | 0.65 | KMT2A (0.42) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL307624 | 0.65 | KMT2A (0.42) | MEN1KMT2AKDM4E | |
| SCHEMBL10481572 | 0.63 | KMT2A (0.50) | ALDH1A1POLQNR1H3MEN1KMT2A | |
| SCHEMBL29184152 | 0.62 | PKM (0.43) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL307698 | 0.62 | OPRK1 (0.47) | KMT2AKDM4E | |
| SCHEMBL3306087 | 0.62 | POLQ (0.46) | ALDH1A1POLQNR1H3 | |
| SCHEMBL4746141 | 0.62 | KMT2A (0.51) | ALDH1A1POLQNR1H3MEN1KMT2A | |
| SCHEMBL9001838 | 0.61 | PKM (0.45) | ALDH1A1NR1H3MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718693-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| WO-2009074518-A1 | COMBINATIONS OF PROLINAMIDE P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | ALDH1A1 2150/4885POLQ 3870/4885NR1H3 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.